Abstract S3 09: Patient reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus …

Background: Relatively little is known about treatment-related endocrine symptoms, sexual function and QoL in premenopausal women receiving adjuvant endocrine therapy with or without OFS. SOFT is the first trial providing patient-reported data in premenopausal women undergoing OFS combined with T vs. tamoxifen alone for five years.Methods: Between Nov 2003 and Apr 2011, 3,066 premenopausal patients with HR+ BC were enrolled in the phase III trial SOFT, of whom 2,045 were randomly assigned to receive adjuvant treatment with 5 years T or T+OFS. A third group received exemestane+OFS and is not included in this report. Prior chemotherapy was allowed, provided women had confirmed premenopausal estradiol levels within 8 months of completing chemotherapy. Patients completed a questionnaire consisting of several global (physical well-being, mood, coping effort, treatment burden) and …